BusinessHorizon Pharma plc Presents New Data Analyses Further Demonstrating Clinical Benefit of KRYSTEXXA® (pegloticase) in Patients with Uncontrolled GoutBy Nasdaq OMXJun 14, 2017, 1:05 PM UTC